Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2021

Oct 19, 2021

SELL
$102.33 - $144.73 $4.94 Million - $6.98 Million
-48,250 Closed
0 $0
Q2 2021

Aug 02, 2021

SELL
$113.03 - $155.64 $29,952 - $41,244
-265 Reduced 0.55%
48,250 $6.33 Million
Q1 2021

May 17, 2021

SELL
$99.52 - $215.83 $4.28 Million - $9.28 Million
-42,978 Reduced 46.97%
48,515 $7.4 Million
Q4 2020

Feb 05, 2021

SELL
$80.55 - $106.05 $1.07 Million - $1.41 Million
-13,285 Reduced 12.68%
91,493 $9.1 Million
Q3 2020

Nov 13, 2020

SELL
$89.56 - $126.72 $529,389 - $749,041
-5,911 Reduced 5.34%
104,778 $9.99 Million
Q2 2020

Aug 03, 2020

BUY
$68.28 - $123.65 $7.56 Million - $13.7 Million
110,689 New
110,689 $12.4 Million
Q3 2019

Nov 12, 2019

SELL
$86.25 - $120.16 $12.9 Million - $18 Million
-149,786 Closed
0 $0
Q2 2019

Jul 26, 2019

SELL
$107.38 - $129.34 $316,019 - $380,647
-2,943 Reduced 1.93%
149,786 $17.1 Million
Q1 2019

May 07, 2019

BUY
$105.93 - $142.47 $4.39 Million - $5.91 Million
41,463 Added 37.26%
152,729 $19.2 Million
Q4 2018

Feb 13, 2019

BUY
$128.36 - $272.13 $5.46 Million - $11.6 Million
42,567 Added 61.96%
111,266 $15.1 Million
Q3 2018

Nov 13, 2018

SELL
$211.18 - $274.49 $4.55 Million - $5.92 Million
-21,555 Reduced 23.88%
68,699 $18.9 Million
Q2 2018

Aug 09, 2018

SELL
$150.77 - $207.98 $837,075 - $1.15 Million
-5,552 Reduced 5.8%
90,254 $18.7 Million
Q1 2018

May 15, 2018

BUY
$138.63 - $182.62 $839,820 - $1.11 Million
6,058 Added 6.75%
95,806 $15.8 Million
Q4 2017

Feb 14, 2018

BUY
$128.36 - $147.04 $3.58 Million - $4.1 Million
27,889 Added 45.08%
89,748 $12.3 Million
Q3 2017

Nov 14, 2017

BUY
$120.91 - $137.94 $7.48 Million - $8.53 Million
61,859
61,859 $8.42 Million

Others Institutions Holding LGND

About LIGAND PHARMACEUTICALS INC


  • Ticker LGND
  • Exchange OTC
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 16,882,800
  • Market Cap $1.88B
  • Description
  • Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing or acquiring technologies that help pharmaceutical companies to discover and develop medicines worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Veklury for the treatment of moderate or severe COVID-19;...
More about LGND
Track This Portfolio

Track Redwood Investments, LLC Portfolio

Follow Redwood Investments, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Redwood Investments, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Redwood Investments, LLC with notifications on news.